Meticulous Research® recently released a comprehensive report titled ELISA Market Size, Share, Forecast, & Trends Analysis by Type (Direct, Sandwich, Competitive), Offering (Analyzer, Software), Technology (Chemiluminescence, Colorimetry, Fluorescence), Application (Research, Diagnostic), End User—Global Forecast to 2031. The report details the growth, trends, and projections for the ELISA (enzyme-linked immunosorbent assay) market, which is anticipated to reach $32.69 billion by 2031, expanding at a 6.1% CAGR from 2024 to 2031.

Request For Sample Report: https://www.meticulousresearch.com/request-sample-report/cp_id=5997?

Growth Drivers and Challenges
The ELISA market's growth is largely fueled by the rising burden of chronic and infectious diseases, an expanding scope of ELISA applications in clinical settings, technological advancements in ELISA methods, and increased use of ELISA across the food industry. However, obstacles like the potential for false positive results and high antibody preparation costs are expected to limit market expansion. Despite these challenges, growing research in emerging markets, a focus on biomarker research, and an emphasis on vaccine development are creating new opportunities. On the other hand, stringent regulations for alternative diagnostic technologies present a significant hurdle for the industry.

Key Players
Leading companies in the ELISA market include Thermo Fisher Scientific Inc. (U.S.), Merck KGaA (Germany), Bio-Rad Laboratories Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Danaher Corporation (U.S.), QIAGEN N.V. (Netherlands), Agilent Technologies, Inc. (U.S.), Abbott Laboratories (U.S.), bioMérieux SA (France), Revvity Inc. (U.S.), QuidelOrtho Corporation (U.S.), Becton, Dickinson and Company (U.S.), Repligen Corporation (U.S.), BioLegend (U.S.), and Bio-Techne Corporation (U.S.).

Market Segmentation
The ELISA market is categorized by type, including Direct, Indirect, Sandwich, and Competitive ELISA. Among these, Indirect ELISA is projected to hold the largest share in 2024, representing 43.5% of the market. This dominance is attributed to its high sensitivity, crucial for diseases like HIV and Lyme disease, where reducing false positives is essential. Indirect ELISA also has cost benefits due to the limited need for labeled antibodies.
Regarding offerings, kits & assays dominate, expected to make up 85.2% of the market in 2024. The large share is due to increased R&D in drug discovery and high use of ELISA kits for biomarker analysis. With recurring purchases, the demand for kits remains high, especially for precise antigen concentration assessments in unknown samples. The technology segment highlights colorimetric ELISA as a leader due to its cost-effectiveness, low sample requirements, and ease of use. Colorimetric absorbance technology, known for accurate quantification, makes it a preferred choice, especially in smaller labs and research facilities.

Applications and End Users
Diagnostic applications, including detecting infectious diseases, cancers, and autoimmune conditions, are expected to lead in market share by 2024, driven by the global rise in cancer incidence. According to GLOBOCAN, cancer prevalence is projected to rise from 20 million in 2022 to 32.6 million cases by 2045. Diagnostic laboratories also constitute a major end-user segment, fueled by chronic disease prevalence and a rising number of laboratories adopting ELISA kits for diagnostics.

Regional Insights
North America is forecasted to hold the largest regional market share in 2024, representing 37.7%. Factors contributing to this share include advanced healthcare infrastructure, robust R&D funding, and the presence of leading market players. The expansion of research facilities, such as Thermo Fisher’s $59 million investment in a Kentucky lab in 2022, underscores North America's market strength.

Buy Now: https://www.meticulousresearch.com/Checkout/88327546?

About Meticulous Research®
Meticulous Research® was founded in 2010 and incorporated as Meticulous Market Research Pvt. Ltd. in 2013 as a private limited company under the Companies Act, 1956. Since its incorporation, the company has become the leading provider of premium market intelligence in North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
The name of our company defines our services, strengths, and values. Since the inception, we have only thrived to research, analyze, and present the critical market data with great attention to detail. With meticulous primary and secondary research techniques, we have built strong capabilities in data collection, interpretation, and analysis of data including qualitative and quantitative research with the finest team of analysts. We design our meticulously analyzed intelligent and value-driven syndicate market research reports, custom studies, quick turnaround research, and consulting solutions to address business challenges of sustainable growth.

Contact Us:
Meticulous Research®
Email- [email protected]
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research